Replies to post #16095 on Predictive Technology Group Inc (PRED)

[Brian903]

Great insight, thank you for sharing.

[happy gylmore]

Hey Thomas, out of the 9300 specialist that are registered for the conference. How many of them will find what we offer "new" to them. By that I mean how many new customers may come out of this for our new product. Any idea ? Thanks

[speedo94947]

HI Thomas, can you tell us the Managements thoughts on the stock activity (if they have any)

[Tippietoes]

 Thomas, any truth to the rumor of PRED listing on OTCQX?  I had heard nasdaq was sending an Infiniti QX to pick Brad up at the airport for the bell ringing ceremony and think this is where the rumor started.

[patience_in_waiting]

Hey Thomas - How concerned is PRED management with uplisting to NASDAQ?

When it finally happens, can we all party in Vegas together, and burn the city to the ground?!

[Investorr]

$3.3 Billion in revenue just in United States sounds amazing. Thanks Thomas.

I’m hoping someone works up revenue estimates for China. I’m told that could be much 2x-4x higher!

Then maybe we figure up worldwide revenue...

It’s not too hard to see where this is headed over the next few years.

[High_Profits]

Amazing ArtGuide Numbers - thanks Thomas for your estimates



ARTguide™ Market:
The market revenue from ARTguide™ is rather simple (remember there are 24 million endometriosis symptomatic undiagnosed women in the U.S.) and the below data does not include Preeclampsia, ART (IVF), and many other indications;

Survey data indicates all fertility clinics are interested in ARTguide™;
A significant percentage (35 to 40%) of those clinics will order the ARTguide™ test for new patients;
And new and existing female patients equal an average of 35 prescriptions per month per doctor.

Initially, 15 larger clinics for clinical research are interested, and;
Assume 12 (of the 15 clinics), each with 9 doctors will produce $150 million in annual revenue from the ARTguide™ diagnostic;
Now consider 200 infertility doctors in the U.S. prescribing 35 prescriptions per month, which generates over $3.3 billion in yearly revenue.

There are 480+ female reproduction and fertility doctors identified (highly confident) that will use ARTguide™ in the U.S.

ENDOMETRIOSIS:
The 2019 American Society for Reproductive Medicine (ASRM) will be attended by 9,300 reproductive doctors, specialists, and scientists, from 94 countries, representing a diagnosed endometriosis population of 176 million, and an estimated undiagnosed population of another 128 million women (for those that have been paying attention, China has 74+ million women diagnosed with endometriosis).

PREECLAMPSIA:
Preeclampsia affects 5-8%, or approximately 300,000, pregnancies every year in the United States, and approximately 1.25 million pregnancies in China, causing severe adverse maternal and fetal outcomes, including significant blood loss, organ failure, disability or even death. Globally, preeclampsia is a leading cause of pregnancy complications, preterm births, and related disabilities. The deaths of approximately 76,000 mothers and 500,000 babies annually worldwide are attributable to preeclampsia. [url]Imprecise diagnostic tools hamper healthcare providers, even in medically advanced countries.

Consider PRED's U.S. and internationally patented ARTguide™ diagnostic is now launched at the world's leading reproductive conference (ASRM) attended by over 9,300 reproductive specialists, representing a global diagnosed and undiagnosed endometriosis population of 300+ million women.

the Figures above DO NOT Include foreign markets like China so assume 3x those figures once added and implemented

and Japan has the highest endometriosis per capita of all Asian populations - next stop Tokyo, India, etc. per Thomas